Chimeric: Media Thread, page-692

https://www.fiercepharma.com/pharma/japans-ono-pays-24-billion-qinlock-maker-deciphera

Another acquisition for $2.4 billion at a 75% premium to Deciphera Pharmaceuticals Friday closing price.

Looks like they have several clinical studies underway. One cancer drug has already been approved and another candidate has been submitted to the regulators for approval.

Ripretinib is approved as a 4th line cancer treatment. It is an orally administered switch-control kinase inhibitor engineered using our proprietary drug discovery platform and developed for the treatment of gastrointestinal stromal tumor, or GIST

https://www.deciphera.com/pipeline/ripretinib

Vimseltinib is in the hands of the regulators. This to me looks like a much bigger market opportunity.

Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. TGCT is a rare disease caused by a genetic translocation in the colony-stimulating factor 1 (CSF1) gene resulting in overproduction of CSF1, triggering migration of inflammatory cells including CSF1R-expressing tumor-associated macrophages (TAMs) to tumor sites. TGCT is also known as giant cell tumor of the tendon sheath (GCT-TS) or pigmented villonodular synovitis (PVNS), a diffuse-type of TGCT. These tumors can grow and cause damage to surrounding tissues and structures inducing pain, joint stiffness, restricted mobility, joint damage, and negative quality of life impact swelling. Surgery is the main treatment option; however, these tumors tend to recur. If untreated, or if the tumor continually recurs, damage and degeneration may occur in the affected joint and surrounding tissues, which may cause significant disability.

https://www.deciphera.com/pipeline/vimseltinib